Patents by Inventor Timothy G. Dixon
Timothy G. Dixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230226119Abstract: The present invention provides universal donor cellular populations derived from umbilical cords possessing ability to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.Type: ApplicationFiled: December 2, 2022Publication date: July 20, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon
-
Publication number: 20230192901Abstract: Disclosed are means, methods and compositions of matter useful for treatment of inflammatory pulmonary diseases such as COVID-19 through administration of agents that facilitate interaction between immune modulatory cells and endogenous pulmonary progenitor cells. In one embodiment a bispecific antibody capable of facilitating the interaction between CD25 on T regulatory cells and CD47 on pulmonary epithelial stem cells is described.Type: ApplicationFiled: November 17, 2022Publication date: June 22, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
-
Publication number: 20230107484Abstract: Disclosed are methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.Type: ApplicationFiled: October 4, 2022Publication date: April 6, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Publication number: 20230090980Abstract: Disclosed are novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.Type: ApplicationFiled: September 22, 2022Publication date: March 23, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Kalina O'Connor
-
Publication number: 20230085607Abstract: Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.Type: ApplicationFiled: September 13, 2022Publication date: March 16, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Publication number: 20230057957Abstract: The invention discloses means of treating lung degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells alone, and/or using said cells under conditions that are activated in order to endow enhanced regenerative activity. In one embodiment said activation of said mesenchymal stem cells is performed through stimulation with a toll like receptor agonist at a concentration and duration sufficient to induce a >50% increase in keratinocyte growth factor expression from said stem cells. In another embodiment the invention provides the use of JadiCells as a means of producing exosomes, wherein said exosomes possess therapeutic properties capable of reducing inflammation, fibrosis and degeneration associated with COPD, as well as stimulation of regenerative activity. In some JadiCells are activated by a treatment with Activated Protein C.Type: ApplicationFiled: August 23, 2022Publication date: February 23, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER, Famela RAMOS
-
Publication number: 20230057356Abstract: Disclosed are means, compositions of matter and protocols useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.Type: ApplicationFiled: August 18, 2022Publication date: February 23, 2023Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.Inventors: Thomas C. ICHIM, Famela RAMOS, James VELTMEYER, Timothy G. DIXON, Wais KAIHANI
-
Publication number: 20230047535Abstract: Disclosed are means, compositions of matter and protocols useful for treatment of neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate neurogenesis.Type: ApplicationFiled: August 11, 2022Publication date: February 16, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. ICHIM, Timothy G. DIXON, Amit N. PATEL, Famela RAMOS, James VELTMEYER
-
Publication number: 20230010501Abstract: Disclosed are means, methods and compositions of matter for treatment Parkinson's Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson's Disease is treated by augmentation of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.Type: ApplicationFiled: July 6, 2022Publication date: January 12, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer, Kalina O'Connor
-
Publication number: 20220403330Abstract: Disclosed are novel means, protocols, and compositions of matter for eliciting an immune response against blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the ?-Gal epitope (Gal?1,3Gal?1,4G1cNAc-R).Type: ApplicationFiled: May 19, 2022Publication date: December 22, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin
-
Publication number: 20220395540Abstract: Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.Type: ApplicationFiled: June 9, 2021Publication date: December 15, 2022Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.Inventors: James Veltmeyer, Thomas E. Ichim, Timothy G. Dixon
-
Publication number: 20220370499Abstract: Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the ?-Gal epitope (Gal?1,3Gal?1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.Type: ApplicationFiled: May 19, 2022Publication date: November 24, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Publication number: 20220370561Abstract: Disclosed are compositions of matter, therapeutics, and protocols useful for reduction and/or reversion of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy, wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length in pulmonary tissue.Type: ApplicationFiled: May 19, 2022Publication date: November 24, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Wals Kaihani, Famela Ramos, James Veltmeyer
-
Patent number: 11504410Abstract: Disclosed are means, compositions of matter, and protocols useful for neuroprotection and neuroregeneration. In one embodiment the invention provides administration of pterostilbene alone or in combination with other ingredients to induce neuroprotection and/or neuroregeneration. The invention teaches protection/regeneration in conditions associated with neurological inflammation and/or other congenital or acquired neurodegenerative diseases.Type: GrantFiled: July 28, 2021Date of Patent: November 22, 2022Assignee: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer
-
Publication number: 20220362341Abstract: Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.Type: ApplicationFiled: May 13, 2022Publication date: November 17, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. ICHIM, Timothy G. DIXON, Kalina O'CONNOR, Wais KAIHANI
-
Publication number: 20220323547Abstract: Disclosed are compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.Type: ApplicationFiled: April 13, 2022Publication date: October 13, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer, Kalina O'Connor
-
Publication number: 20220306994Abstract: Disclosed are means, methods and compositions of matter useful for induction of immunological responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction. In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.Type: ApplicationFiled: March 18, 2022Publication date: September 29, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. ICHIM, Timothy G. DIXON, Feng LIN, Famela RAMOS, James VELTMEYER
-
Publication number: 20220298491Abstract: Disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.Type: ApplicationFiled: March 16, 2022Publication date: September 22, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. ICHIM, Famela RAMOS, James VELTMEYER, Timothy G. DIXON
-
Publication number: 20220280574Abstract: The invention discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment, monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory as well as regenerative properties useful in reducing suicidal ideations and/or attempts.Type: ApplicationFiled: March 4, 2022Publication date: September 8, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Famela Ramos, Kalina O'Connor, James Veltmeyer
-
Publication number: 20220267730Abstract: Disclosed are means, methods and compositions of matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and used for the purposes of immunotherapy.Type: ApplicationFiled: February 22, 2022Publication date: August 25, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Feng LIN, Famela Ramos, James Veltmeyer